Wang, Anthony Z.
Bowman-Kirigin, Jay A.
Desai, Rupen
Kang, Liang-I
Patel, Pujan R.
Patel, Bhuvic
Khan, Saad M.
Bender, Diane
Marlin, M. Caleb
Liu, Jingxian
Osbun, Joshua W.
Leuthardt, Eric C.
Chicoine, Michael R.
Dacey, Ralph G. Jr
Zipfel, Gregory J.
Kim, Albert H.
DeNardo, David G.
Petti, Allegra A.
Dunn, Gavin P.
Funding for this research was provided by:
Lloyd J. Old Cancer Research Institute STAR Award
Article History
Received: 22 August 2021
Accepted: 21 April 2022
First Online: 10 May 2022
Declarations
:
: All patient samples were obtained with written informed consent from patients meeting selection criteria following the Washington University School of Medicine Institutional Review Board Protocol #202107071. This study was approved by the Institutional Review Board at Washington University in St. Louis. This study conforms to the principles of the Helsinki Declaration.
: Not applicable
: GPD is a member of the Scientific Advisory Board of Ziopharm Oncology, the clinical advisory board of ImmunoGenesis, and is a co-founder of Immunovalent.AHK has received research grants from Monteris Medical for a mouse laser therapy study as well as from Stryker and Collagen Matrix for clinical outcomes studies about a dural substitute, which have no direct relation to this study.ECL has listed the following competing interests: Acera; Alcyone; Caeli Vascular; Cerovations; E15; Immunovalent; inner Cosmos; Intellectual Ventures; Kinexus; Monteris; Neuroloutions, Inc.; Osteovantage, Inc.; Pear Therapeutics, Inc.; red devil 4; Sante Ventures; Sora Imaging Solutions; SympEL Neuromodulation.The remaining authors declare that they have no competing interests.